Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Hess

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Autophagy|February 9, 2008
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3Hiroshi Aoki, Yasuko Kondo, Kenneth Aldape, et al.
Oncotarget|April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerZhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Thyroid : Official Journal of the American Thyroid Association|January 11, 2017
Patterns of Treatment Failure in Anaplastic Thyroid CarcinomaSarika N Rao, Mark Zafereo, Ramona Dadu, et al.
Clinical Epigenetics|March 26, 2015
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapyApostolia M Tsimberidou, Rabih Said, Kirk Culotta, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation TrialVivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Autophagy|February 9, 2008
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3Hiroshi Aoki, Yasuko Kondo, Kenneth Aldape, et al.
Oncotarget|April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerZhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Thyroid : Official Journal of the American Thyroid Association|January 11, 2017
Patterns of Treatment Failure in Anaplastic Thyroid CarcinomaSarika N Rao, Mark Zafereo, Ramona Dadu, et al.
Clinical Epigenetics|March 26, 2015
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapyApostolia M Tsimberidou, Rabih Said, Kirk Culotta, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation TrialVivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
Pageof 10